Today, CureDuchenne Ventures is pleased to share that we made a research investment into Code BioTherapeutics and their next-generation gene therapy platform. This is a promising technology aimed at overcoming […]
Built by the community, for the community, the DuchenneXchange has offered a secure place to inform, inspire and empower those living with Duchenne since its inception in 2018. By offering […]
CureDuchenne’s webinar, COVID-19 Vaccines: What the Duchenne Community Needs to Know, was an opportunity for the Duchenne community to get reliable information on COVID-19 vaccines. A panel of experts from […]
Dear Committee Members, On behalf of individuals living with Duchenne muscular dystrophy, their families, and caregivers served by CureDuchenne, I am writing to urge the Committee to include individuals with Duchenne in its recommendations for sub-populations to receive approved or authorized COVID-19 […]
Debra Miller, Founder and CEO of CureDuchenne, and Dr. Peter Marks, Director of the Center for Biological Evaluation and Research of the FDA, were featured at a Fireside Chat at […]
The Coronavirus Aid, Relief, and Economic Security (CARES) Act encourages charitable giving by increasing tax incentives for individuals and corporations. We want to make sure that anyone who supports us […]
CureDuchenne is pleased to share the news that Edgewise Therapeutics is starting a Phase 1 clinical trial to assess the safety, tolerability, and appropriate dose of their experimental therapeutic aimed […]
CureDuchenne Ventures is happy to announce an investment in Mesentech, a company based in Vancouver, Canada, that has a novel therapeutic approach for improving bone density and strength. This investment […]
